JP2001515033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001515033A5 JP2001515033A5 JP2000509411A JP2000509411A JP2001515033A5 JP 2001515033 A5 JP2001515033 A5 JP 2001515033A5 JP 2000509411 A JP2000509411 A JP 2000509411A JP 2000509411 A JP2000509411 A JP 2000509411A JP 2001515033 A5 JP2001515033 A5 JP 2001515033A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- medicament
- hydrogen
- formula
- gaba analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229960002870 gabapentin Drugs 0.000 description 5
- 229960001233 pregabalin Drugs 0.000 description 5
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229960003940 naproxen sodium Drugs 0.000 description 3
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical group [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- IUVMAUQEZFTTFB-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound CC1CC(CN)(CC(O)=O)CC1C IUVMAUQEZFTTFB-UHFFFAOYSA-N 0.000 description 1
- UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical group CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 description 1
- HYVKVSAZCPKHDV-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclopentyl]acetic acid Chemical compound CC1CCC(CN)(CC(O)=O)C1 HYVKVSAZCPKHDV-UHFFFAOYSA-N 0.000 description 1
- IRQCKMBXGOKUDW-UHFFFAOYSA-N 3-(1-azaniumylethyl)-5-methylhexanoate Chemical compound CC(C)CC(C(C)N)CC(O)=O IRQCKMBXGOKUDW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 208000007996 nephrogenic syndrome of inappropriate antidiuresis Diseases 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5675397P | 1997-08-20 | 1997-08-20 | |
| US60/056,753 | 1997-08-20 | ||
| US7479498P | 1998-02-16 | 1998-02-16 | |
| US60/074,794 | 1998-02-16 | ||
| US8293698P | 1998-04-24 | 1998-04-24 | |
| US60/082,936 | 1998-04-24 | ||
| PCT/US1998/017082 WO1999008671A1 (en) | 1997-08-20 | 1998-08-18 | Gaba analogs to prevent and treat gastrointestinal damage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001515033A JP2001515033A (ja) | 2001-09-18 |
| JP2001515033A5 true JP2001515033A5 (https=) | 2006-01-05 |
| JP4681116B2 JP4681116B2 (ja) | 2011-05-11 |
Family
ID=27369092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000509411A Expired - Fee Related JP4681116B2 (ja) | 1997-08-20 | 1998-08-18 | 胃腸損傷を防止および治療するためのｇａｂａ類縁体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6242488B1 (https=) |
| EP (1) | EP1009399B1 (https=) |
| JP (1) | JP4681116B2 (https=) |
| KR (2) | KR100609359B1 (https=) |
| AT (1) | ATE461698T1 (https=) |
| AU (2) | AU8668598A (https=) |
| BR (1) | BR9812133A (https=) |
| CA (1) | CA2297163C (https=) |
| CO (1) | CO4960645A1 (https=) |
| CY (1) | CY1109981T1 (https=) |
| DE (1) | DE69841574D1 (https=) |
| DK (1) | DK1009399T3 (https=) |
| ES (1) | ES2341154T3 (https=) |
| HU (1) | HUP0004551A3 (https=) |
| IL (1) | IL134164A (https=) |
| IS (1) | IS2749B (https=) |
| MY (1) | MY155223A (https=) |
| NO (1) | NO327983B1 (https=) |
| NZ (1) | NZ502729A (https=) |
| PE (1) | PE107299A1 (https=) |
| PL (1) | PL194125B1 (https=) |
| PT (1) | PT1009399E (https=) |
| TW (2) | TWI251485B (https=) |
| UY (1) | UY25148A1 (https=) |
| WO (2) | WO1999008670A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
| JP3782935B2 (ja) | 1997-09-08 | 2006-06-07 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法 |
| EP1031350A1 (en) * | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| US6451857B1 (en) | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| DK1169060T3 (da) * | 1999-04-09 | 2006-01-16 | Euro Celtique Sa | Natriumkanalblokkerpræparater og anvendelse deraf |
| EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| ES2287021T3 (es) | 1999-07-22 | 2007-12-16 | University Of Rochester | Metodo para el tratamiento de sintomas de variacines hormonales que incluyen el fogaje. |
| FR2801217B1 (fr) * | 1999-11-24 | 2002-12-06 | Aventis Pharma Sa | Association de riluzole et de gabapentine et son utilisation comme medicament |
| EP1294854A2 (en) * | 2000-05-16 | 2003-03-26 | Warner-Lambert Company | Cell line for the expression of an alpha2-delta2 calcium channel subunit |
| AU2002211863A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| EP1226820A1 (en) | 2001-01-26 | 2002-07-31 | Warner-Lambert Company | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| CA2449729C (en) | 2001-06-11 | 2009-11-03 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| AU2002345638A1 (en) | 2001-06-11 | 2002-12-23 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| DK1423168T3 (da) * | 2001-09-03 | 2006-05-15 | Newron Pharm Spa | Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| PL372210A1 (en) * | 2002-02-22 | 2005-07-11 | Warner-Lambert Company Llc | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
| AU2003222033A1 (en) | 2002-03-20 | 2003-10-08 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
| AU2003243180A1 (en) | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| AU2003247042A1 (en) * | 2002-07-10 | 2004-02-02 | Warner-Lambert Company Llc | Gastrointestinal compositions comprising gaba derivatives |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| US7060727B2 (en) | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
| AU2003303041B2 (en) * | 2002-12-13 | 2008-07-24 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
| EP1572187A1 (en) * | 2002-12-13 | 2005-09-14 | Warner-Lambert Company LLC | Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| BRPI0408110A (pt) | 2003-03-07 | 2006-03-01 | Warner Lambert Co | derivados de beta-aminoácido substituìdos com tetrazol e oxadiazolona |
| WO2004084881A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| KR20060119971A (ko) | 2003-09-11 | 2006-11-24 | 제노포트 인코포레이티드 | Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방 |
| NZ579515A (en) | 2003-09-17 | 2011-09-30 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| SG147437A1 (en) | 2003-10-14 | 2008-11-28 | Xenoport Inc | Crystalline form of gamma-aminobutyric acid analog |
| PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
| ES2292107T3 (es) * | 2004-03-12 | 2008-03-01 | Warner-Lambert Company Llc | Ligandos de bifosfina simetricos en c1 y su uso en la sintesis asimetrica de pregabalina. |
| EP1735324B1 (en) * | 2004-04-01 | 2008-08-20 | Warner-Lambert Company LLC | Preparation of p-chirogenic phospholanes and their use in asymetric synthesis |
| HRP20100054T1 (hr) * | 2004-06-21 | 2010-05-31 | Warner-Lambert Company Llc | Dobivanje pregabalina i njemu sličnih spojeva |
| DK1809271T5 (da) * | 2004-09-10 | 2010-12-06 | Newron Pharm Spa | Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer |
| MX2007005306A (es) | 2004-11-04 | 2007-06-11 | Xenoport Inc | Formas de dosis oral de liberacion sostenida de la prodroga gabapentina. |
| EP1963280B1 (en) | 2005-12-22 | 2015-10-28 | Newron Pharmaceuticals S.p.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
| US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US20080161393A1 (en) * | 2006-12-08 | 2008-07-03 | Barrett Ronald W | Use of prodrugs of GABA analogs for treating disease |
| CA2703472A1 (en) * | 2007-10-26 | 2009-04-30 | The Scripps Research Institute | Methods for treating substance dependence |
| ES2601852T3 (es) | 2008-01-25 | 2017-02-16 | Xenoport, Inc. | Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| EP2250148B1 (en) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
| TWI504393B (zh) * | 2009-06-22 | 2015-10-21 | 惠氏有限責任公司 | 製備包含異丁苯丙酸鈉之醫藥組合物之方法 |
| WO2011141923A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
| WO2012059797A1 (en) | 2010-11-04 | 2012-05-10 | Lupin Limited | Process for synthesis of (s) - pregabalin |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| CA2903000C (en) | 2013-01-28 | 2021-10-12 | Hector L. Lopez | Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor |
| CN105997970A (zh) * | 2015-12-16 | 2016-10-12 | 南昌大学 | γ-氨基丁酸在制备胃粘膜保护剂中的应用 |
| WO2017177160A1 (en) * | 2016-04-07 | 2017-10-12 | Nevakar Llc | Formulation for use in a method of treatment of pain |
| WO2019070641A1 (en) | 2017-10-03 | 2019-04-11 | Nevakar Inc. | COMBINATIONS OF ACETAMINOPHENE-PRÉGABALINE AND METHODS OF TREATING PAIN |
| CA3099775A1 (en) | 2018-05-14 | 2019-11-21 | Xgene Pharmaceutical Inc. | Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin |
| CN116999560A (zh) * | 2022-04-30 | 2023-11-07 | 武汉思瓴生物科技有限公司 | 可治疗疼痛的药物组合及其应用 |
| EP4648757A4 (en) * | 2023-02-17 | 2026-01-07 | Ovid Therapeutics Inc | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID FOR THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND AS AN IMMUNOMODULATING AGENT |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE634102A (https=) | ||||
| DE1963925C3 (de) | 1969-12-20 | 1975-07-10 | Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg | Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins |
| JPS54110334A (en) | 1978-02-16 | 1979-08-29 | Fuji Chem Ind Co Ltd | Novel compounded anodyne and antiiinflammatory agent |
| US4158581A (en) | 1978-04-14 | 1979-06-19 | Westinghouse Electric Corp. | Method of making magnetic component for direct current apparatus |
| JPS61221121A (ja) | 1985-03-27 | 1986-10-01 | Nitto Electric Ind Co Ltd | テ−プ製剤 |
| US4694010A (en) | 1985-08-16 | 1987-09-15 | New York University | Anticonvulsant compositions and method |
| JPH02502546A (ja) | 1987-12-22 | 1990-08-16 | ファーカニー、ジョン ダブリュ | 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤 |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| GB9108362D0 (en) | 1991-04-18 | 1991-06-05 | Radoslavov Alexander | A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions |
| HU222776B1 (hu) | 1992-05-20 | 2003-10-28 | Northwestern University | (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása |
| US5234929A (en) | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
| JPH06100468A (ja) | 1992-09-25 | 1994-04-12 | Kibun Food Chemifa Co Ltd | 徐放性組成物 |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| JPH06227969A (ja) | 1993-02-02 | 1994-08-16 | Masayasu Sugihara | 薬品の腸溶性改善方法およびそれにより得られた薬品組成物 |
| US5420270A (en) | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5352638A (en) | 1994-02-22 | 1994-10-04 | Corning Incorporated | Nickel aluminosilicate glass-ceramics |
| CZ60697A3 (cs) | 1994-09-02 | 1998-02-18 | Virginia Commonwealth University | Farmaceutický prostředek |
| GB9420784D0 (en) * | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
| CN1046199C (zh) | 1994-12-13 | 1999-11-10 | 凌吉安 | 复方消炎止痛霜剂 |
| WO1998007447A1 (en) * | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| WO1998017627A1 (en) * | 1996-10-23 | 1998-04-30 | Warner-Lambert Company | Substituted gamma aminobutyric acids as pharmaceutical agents |
| US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
-
1998
- 1998-07-29 WO PCT/US1998/015694 patent/WO1999008670A1/en not_active Ceased
- 1998-07-29 AU AU86685/98A patent/AU8668598A/en not_active Withdrawn
- 1998-08-18 BR BR9812133-2A patent/BR9812133A/pt not_active Application Discontinuation
- 1998-08-18 WO PCT/US1998/017082 patent/WO1999008671A1/en not_active Ceased
- 1998-08-18 NZ NZ502729A patent/NZ502729A/xx not_active IP Right Cessation
- 1998-08-18 ES ES98945758T patent/ES2341154T3/es not_active Expired - Lifetime
- 1998-08-18 IL IL13416498A patent/IL134164A/xx not_active IP Right Cessation
- 1998-08-18 PL PL98338705A patent/PL194125B1/pl not_active IP Right Cessation
- 1998-08-18 DK DK98945758.5T patent/DK1009399T3/da active
- 1998-08-18 TW TW092130045A patent/TWI251485B/zh not_active IP Right Cessation
- 1998-08-18 AU AU92930/98A patent/AU9293098A/en not_active Abandoned
- 1998-08-18 JP JP2000509411A patent/JP4681116B2/ja not_active Expired - Fee Related
- 1998-08-18 PT PT98945758T patent/PT1009399E/pt unknown
- 1998-08-18 DE DE69841574T patent/DE69841574D1/de not_active Expired - Lifetime
- 1998-08-18 TW TW087113592A patent/TW570794B/zh not_active IP Right Cessation
- 1998-08-18 KR KR1020007001703A patent/KR100609359B1/ko not_active Expired - Fee Related
- 1998-08-18 HU HU0004551A patent/HUP0004551A3/hu unknown
- 1998-08-18 CA CA002297163A patent/CA2297163C/en not_active Expired - Lifetime
- 1998-08-18 AT AT98945758T patent/ATE461698T1/de active
- 1998-08-18 KR KR1020057022543A patent/KR20050116168A/ko not_active Ceased
- 1998-08-18 MY MYPI98003770A patent/MY155223A/en unknown
- 1998-08-18 EP EP98945758A patent/EP1009399B1/en not_active Expired - Lifetime
- 1998-08-19 PE PE1998000745A patent/PE107299A1/es not_active Application Discontinuation
- 1998-08-19 CO CO98047372A patent/CO4960645A1/es unknown
- 1998-08-20 UY UY25148A patent/UY25148A1/es unknown
-
2000
- 2000-01-25 IS IS5361A patent/IS2749B/is unknown
- 2000-02-17 NO NO20000786A patent/NO327983B1/no not_active IP Right Cessation
- 2000-05-09 US US09/567,191 patent/US6242488B1/en not_active Expired - Fee Related
-
2001
- 2001-03-13 US US09/804,742 patent/US6426368B2/en not_active Expired - Fee Related
-
2010
- 2010-04-26 CY CY20101100368T patent/CY1109981T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001515033A5 (https=) | ||
| JP4681116B2 (ja) | 胃腸損傷を防止および治療するためのｇａｂａ類縁体 | |
| JP2002520286A5 (https=) | ||
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| RU98102959A (ru) | Замещенные бензиламинопиперидины | |
| JP2001515859A5 (https=) | ||
| RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| JP2005510540A5 (https=) | ||
| JP2004501189A5 (https=) | ||
| JPH10203996A5 (https=) | ||
| JP2002541198A5 (ja) | 失禁治療用医薬組成物 | |
| BE1007268A3 (fr) | Medicaments pour le traitement d'etats inflammatoires ou pour l'analgesie. | |
| JP2014532728A5 (https=) | ||
| US20130316988A1 (en) | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | |
| IL300130B2 (en) | New combinations for antigen-based therapy | |
| RU97113367A (ru) | Производные нейраминовой кислоты, их получение и применение в медицине | |
| JP2003515583A5 (https=) | ||
| JP2010513551A5 (https=) | ||
| JP2007505105A5 (https=) | ||
| JP2009502777A5 (https=) | ||
| CN1795003A (zh) | 基于锶化合物的抗炎组合物 | |
| ES2343166T3 (es) | Activadores para el receptor activado por proliferador de peroxisoma. | |
| JP2004538314A5 (https=) | ||
| JP2024532807A5 (https=) | ||
| Skeljo et al. | Adaptation of rat gastric mucosa to repeated doses of non‐salicylate non‐steroidal anti‐inflammatory drugs |